keyword
MENU ▼
Read by QxMD icon Read
search

Atezolizumab

keyword
https://www.readbyqxmd.com/read/29678530/improved-overall-survival-and-locoregional-disease-control-with-concurrent-pd-1-pathway-inhibitors-and-stereotactic-radiosurgery-for-lung-cancer-patients-with-brain-metastases
#1
Emily Schapira, Harper Hubbeling, Beow Y Yeap, William A Mehan, Alice T Shaw, Kevin Oh, Justin F Gainor, Helen A Shih
PURPOSE: Despite the emerging role of programmed cell death-1 (PD-1) pathway inhibitors for patients with advanced lung cancer, a paucity of data are available on the activity of these agents among patients with brain metastases. We investigated the outcomes of PD-1 pathway inhibitors and stereotactic radiosurgery (SRS) for the treatment of patients with brain metastases from lung cancer. METHODS AND MATERIALS: We retrospectively reviewed the medical records of non-small-cell lung cancer patients with brain metastases consecutively treated with PD-1 pathway inhibitors and SRS at our institution from 2012 to 2017...
March 22, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29675101/a-network-meta-analysis-comparing-the-efficacy-and-safety-of-anti-pd-1-with-anti-pd-l1-in-non-small-cell-lung-cancer
#2
Wei You, Mei Liu, Ji-Dong Miao, Yu-Qian Liao, Yi-Bing Song, Dian-Kun Cai, Yang Gao, Hao Peng
Background : This network meta-analysis aimed at comparing anti-programmed death 1 (anti-PD-1) with anti-programmed death ligand 1(anti-PD-L1) immunotherapy in patients with metastatic, previously treated non-small cell lung cancer (NSCLC) who failed first-line treatment. Methods : We searched electronic databases to identify all eligible clinical trials. End-points included overall survival (OS), progression-free survival (PFS) and objective response. Hazard ratios (HRs) or odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were extracted...
2018: Journal of Cancer
https://www.readbyqxmd.com/read/29663063/-treatment-with-pd-1-pd-l1-and-ctla-4-immune-checkpoint-inhibitors-immune-mediated-side-effects
#3
REVIEW
M-O Grimm, H Oppel-Heuchel, S Foller
Immune checkpoint inhibitors are a new standard therapy for advanced or metastatic urothelial as well as renal cell carcinoma. Atezolizumab and Pembrolizumab have been approved for the treatment of cisplatin-ineligible patients with transitional call cancer in the 1st line setting; both antibodies and Nivolumab may also be used after platinum based prior therapy. Regarding renal cell carcinoma approval for 1st line treatment with the combination of Nivolumab and Ipilimumab for patients at intermediate or high risk (IMDC) is currently expected...
April 16, 2018: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/29662547/pd-l1-expression-testing-in-non-small-cell-lung-cancer
#4
REVIEW
Cristina Teixidó, Noelia Vilariño, Roxana Reyes, Noemí Reguart
In recent years, immunotherapy has revolutionized and changed the standard of care in patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, fundamentally those that act by blocking the programmed cell death receptor-1 (PD-1) and its ligand the programmed cell death ligand-1 (PD-L1) have emerged as novel treatment strategies in NSCLC, demonstrating undoubted superiority over chemotherapy in terms of efficacy. Several of these immune checkpoint modulators have recently gained regulatory approval for the treatment of advanced NSCLC, such as nivolumab, atezolizumab and pembrolizumab in first-line (only the latter) and second-line settings, and more recently, durvalumab as maintenance after chemoradiotherapy in locally advanced disease...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29644490/emerging-role-of-immunotherapy-in-advanced-urothelial-carcinoma
#5
REVIEW
Vadim S Koshkin, Petros Grivas
PURPOSE OF REVIEW: Advanced urothelial carcinoma (aUC) has long been treated preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible whereas for those who progress on a platinum-based regimen treatment options are limited. We review key recent data regarding immune checkpoint inhibitors that are changing this treatment landscape. RECENT FINDINGS: Since May 2016, five different agents targeting the PD-1/PD-L1 pathway (atezolizumab, pembrolizumab, nivolumab, avelumab, durvalumab) have received FDA approval for the treatment of aUC in the platinum-refractory setting, while pembrolizumab and atezolizumab are FDA-approved for cisplatin-ineligible patients in the first-line setting...
April 11, 2018: Current Oncology Reports
https://www.readbyqxmd.com/read/29623487/atezolizumab-in-metastatic-urothelial-carcinoma-outside-clinical-trials-focus-on-efficacy-safety-and-response-to-subsequent-therapies
#6
Pedro C Barata, Dhrmesh Gopalakrishnan, Vadim S Koshkin, Prateek Mendiratta, Matt Karafa, Kimberly Allman, Allison Martin, Jennifer Beach, Pam Profusek, Allison Tyler, Laura Wood, Moshe Ornstein, Timothy Gilligan, Brian I Rini, Jorge A Garcia, Petros Grivas
BACKGROUND: Little is known about the outcomes, safety, and response to subsequent therapies of patients with metastatic urothelial carcinoma (mUC) treated with atezolizumab outside clinical trials. OBJECTIVES: The objectives of the study include to report the clinical efficacy and safety of atezolizumab, and the response to future therapies in clinical practice outside clinical trials. PATIENT AND METHODS: This is a retrospective, single-center study including consecutive patients with confirmed mUC who received at least one dose of atezolizumab 1200 mg every 3 weeks between May 2016 and April 2017...
April 6, 2018: Targeted Oncology
https://www.readbyqxmd.com/read/29623110/clinical-assessment-of-immune-related-adverse-events
#7
REVIEW
Aaron Sosa, Esther Lopez Cadena, Cristina Simon Olive, Niki Karachaliou, Rafael Rosell
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across diverse trials. Adverse events of an immune nature associated with these agents frequently affect the skin, colon, endocrine glands, lungs and liver...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29618381/efficacy-of-pd-1-pd-l1-inhibitors-in-older-adults-a-meta-analysis
#8
Rawad Elias, Anita Giobbie-Hurder, Nadine Jackson McCleary, Patrick Ott, F Stephen Hodi, Osama Rahma
BACKGROUND: Immune checkpoint inhibitors targeting PD-1/PD-L1 pathway demonstrated promising activities in variety of malignancies, however little is known regarding their efficacy in adults aged ≥65 years. METHODS: We conducted a systematic review and a study-level meta-analysis to explore efficacy of ICIs based on age, younger vs older than 65 years. We included in this analysis randomized controlled phase II or III studies in patients with metastatic solid tumors that compared efficacy of PD-1 or PD-L1 inhibitors to a non-PD-1/PD-L1 inhibitor...
April 4, 2018: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/29606979/pd-1-and-pd-l1-inhibitors-after-platinum-based-chemotherapy-or-in-first-line-therapy-in-cisplatin-ineligible-patients-dramatic-improvement-of-prognosis-and-overall-survival-after-decades-of-hopelessness-in-patients-with-metastatic-urothelial-cancer
#9
REVIEW
Irene Resch, Shahrokh F Shariat, Kilian M Gust
Until recently, there were no true innovations in the management of locally advanced (aUC) and metastatic urothelial cancer (mUC) in the last three decades. Vinflunine has been approved by the EMA (European Medicines Agency) with only limited improvement compared to best supportive care in second line treatment. In addition, gemcitabine/cisplatin has been established as an alternative to methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC). The advent of checkpoint inhibitors (CPI) revolutionized the care of these patients, transforming a unanimously deadly disease into one with hope through sustained disease control...
2018: Memo
https://www.readbyqxmd.com/read/29593888/immunotherapy-in-previously-treated-non-small-cell-lung-cancer-nsclc
#10
REVIEW
Ticiana A Leal, Suresh S Ramalingam
Treatment with immunotherapy has made a significant impact in the outcomes for those individuals diagnosed with metastatic non-small cell lung cancer (NSCLC) and its use is currently an established treatment modality. In light of recent advances in immunotherapy, improved survival, particularly for patients with stage IV NSCLC, has been reported with durable and prolonged responses in a subset of patients. Immune check point inhibitors, which include nivolumab, pembrolizumab, and atezolizumab, are standard treatment options in the salvage setting...
February 2018: Journal of Thoracic Disease
https://www.readbyqxmd.com/read/29587324/-immunotherapy-for-renal-cell-carcinoma-current-status
#11
Marc-Oliver Grimm, Susan Foller
Systemic treatment of metastatic renal cell carcinoma (mRCC) has substantially changed during the last 2 years due to approval of the immune-checkpoint inhibitor Nivolumab (Opdivo® ) and new multikinase inhibitors (Cabozantinib, Lenvatinib, Tivozanib). The german kidney tumor guideline strongly recommends Nivolumab and Cabozantinib as 2nd line treatments after prior VEGF targeted therapy. CheckMate 025, the prospective randomized trial which led to approval of Nivolumab demonstrated improved overall survival (26 month vs...
April 2018: Aktuelle Urologie
https://www.readbyqxmd.com/read/29587323/-immune-checkpoint-inhibition-in-metastatic-urothelial-carcinoma
#12
Jens Bedke, Tilman Todenhöfer, Arnulf Stenzl
The treatment of metastatic urothelial carcinoma is characterized by the administration of combinatory regimes of chemotherapy. In the first-line treatment theses regimes demonstrate relatively good objective response rates and prolongation of overall survival. The prognosis declines if the patient is refractory to platin in the second- or third-line treatment or if the patient is ineligible for cisplatin in the first-line setting. Cisplatin ineligibility is defined by a poor renal function or subsequent comorbidities...
April 2018: Aktuelle Urologie
https://www.readbyqxmd.com/read/29572003/clinicopathological-characteristics-of-pole-mutation-in-patients-with-non-small-cell-lung-cancer
#13
Zhengbo Song, Guoping Cheng, Chunwei Xu, Wenxian Wang, Yang Shao, Yiping Zhang
BACKGROUND: Mutations in polymerase ε (POLE), a DNA polymerase involved in DNA replication and repair, have been investigated in endometrial cancers and response to programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) immunotherapy. However, the frequency of POLE gene mutation in patients with non-small cell lung cancer (NSCLC) has not been reported. MATERIALS AND METHODS: We assessed POLE mutation in 319 patients with NSCLC by next-generation sequencing (NGS) of 416 cancer-associated genes...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29571563/-pd-l1-testing-in-non-small-cell-lung-carcinoma-guidelines-from-the-pattern-group-of-thoracic-pathologists
#14
Sylvie Lantuejoul, Julien Adam, Nicolas Girard, Mickael Duruisseaux, Audrey Mansuet-Lupo, Aurélie Cazes, Isabelle Rouquette, Laure Gibault, Stéphane Garcia, Martine Antoine, Jean Michael Vignaud, Françoise Galateau-Sallé, Christine Sagan, Cécile Badoual, Frédérique Penault-Llorca, Diane Damotte
Lung cancer is the leading cause of cancer death in France with low response rates to conventional chemotherapy. Nevertheless, new therapies have emerged recently, among which PD1 immune checkpoint inhibitors (ICI), such as nivolumab (OPDIVO® , Bristol-Myers Squibb) and pembrolizumab (KEYTRUDA® , Merck & Co), or PD-L1 ICI, such as atezolizumab (TECENTRIQ® , Genentech), durvalumab (IMFINZI® , Astra-Zeneca), and avelumab (BAVENCIO® , EMD Serono). The prescription of pembrolizumab for advanced stages non-small cell lung carcinoma (NSCLC) patients requires the demonstration of PD-L1 expression by tumor cells by immunohistochemistry (IHC) (minimum of 50% of positive tumor cells is required for first-line setting, and of 1% for second-line and beyond) and PD-L1 assay is now considered as a companion diagnostic tool for this drug...
March 20, 2018: Annales de Pathologie
https://www.readbyqxmd.com/read/29562804/a-network-meta-analysis-of-the-pd-l-1-inhibitors-in-the-salvage-treatment-of-urothelial-bladder-cancer
#15
Elie El Rassy, Ziad Bakouny, Fouad Aoun, Fadi G Haddad, Ghassan Sleilaty, Tarek Assi, Joseph Kattan
AIM: To determine which of the approved immune checkpoint inhibitors is the optimal treatment in metastatic urothelial bladder cancer. METHODS & MATERIALS: Only the pivotal Phase III trials of second-line metastatic urothelial bladder cancer were included in this network meta-analysis. RESULTS: This NMA included three pooled trials (NCT00315237, NCT02256436 and NCT02302807) of 1125 participants. Pembrolizumab was the only treatment with positive effect on overall survival compared with the best supportive care...
March 22, 2018: Immunotherapy
https://www.readbyqxmd.com/read/29545941/efficacy-of-pd-1-pd-l1-inhibitors-against-pretreated-advanced-cancer-a-systematic-review-and-meta-analysis
#16
Hao Hu, Qian Zhu, Xian Shi Luo, Xiong Wen Yang, Hai Dong Wang, Chang Ying Guo
Background: Programmed cell death 1 (PD-1) and programmed cell death-ligand 1(PD-L1) inhibitors have captured our attention as new therapeutic options for several tumor types. Nonetheless, the differences in efficacy between PD-1/PD-L1 inhibitors and conventional treatments (chemotherapy or targeted therapy) in pretreated advanced cancer patients remain unclear. Materials and Methods: A systematic literature search was conducted to identify phase III randomized controlled trials (RCTs)-based investigations of PD-1(nivolumab, pembrolizumab)/PD-L1 inhibitors (atezolizumab) against pretreated advanced cancer...
February 20, 2018: Oncotarget
https://www.readbyqxmd.com/read/29540345/immune-related-adverse-events-for-anti-pd-1-and-anti-pd-l1-drugs-systematic-review-and-meta-analysis
#17
REVIEW
Shrujal Baxi, Annie Yang, Renee L Gennarelli, Niloufer Khan, Ziwei Wang, Lindsay Boyce, Deborah Korenstein
OBJECTIVE: To evaluate rates of serious organ specific immune-related adverse events, general adverse events related to immune activation, and adverse events consistent with musculoskeletal problems for anti-programmed cell death 1 (PD-1) drugs overall and compared with control treatments. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, Cochrane Library, Web of Science, and Scopus searched to 16 March 2017 and combined with data from ClinicalTrials...
March 14, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29525401/targeting-immune-checkpoints-in-non-small-cell-lung-cancer
#18
REVIEW
Andrea Bianco, Umberto Malapelle, Danilo Rocco, Fabio Perrotta, Gennaro Mazzarella
Cancers have the ability to disrupt immune response by interfering with adaptive immunity. Blocking checkpoint pathways has become a target for pharmacological research in lung cancer with particular focus on peptides PD-1 and CTLA-4. A number of immune check-point inhibitors (ICIs) targeting both PD-1 and CTLA-4 pathways are under investigation within clinical trials, of which Nivolumab, Pembrolizumab and Atezolizumab have already been approved for lung cancer treatment by both FDA and EMA. Employed as single-agents in current practice for the treatment of advanced non-small cell lung cancer (NSCLC) ICIs have exhibited advantages in terms of overall survival and response rate with some responses being durable...
March 8, 2018: Current Opinion in Pharmacology
https://www.readbyqxmd.com/read/29525239/atezolizumab-in-japanese-patients-with-previously-treated-advanced-non-small-cell-lung-cancer-a-subgroup-analysis-of-the-phase-3-oak-study
#19
Toyoaki Hida, Reiko Kaji, Miyako Satouchi, Norihiko Ikeda, Atsushi Horiike, Hiroshi Nokihara, Takashi Seto, Tomohisa Kawakami, Shintaro Nakagawa, Toshio Kubo
INTRODUCTION: Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) agent, is effective and well tolerated in patients with pretreated advanced non-small-cell lung cancer (NSCLC). We assessed its efficacy and safety in Japanese patients through subgroup analyses of the phase 3 OAK study (NCT02008227). PATIENTS AND METHODS: Key eligibility criteria of this randomized, controlled, open-label, international study include locally advanced/metastatic NSCLC, ≥ 1 prior platinum-based chemotherapy, age ≥ 18 years, measurable disease (Response Evaluation Criteria in Solid Tumors v1...
February 1, 2018: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29517083/durvalumab-for-the-treatment-of-urothelial-carcinoma
#20
M Alsharedi, R Srivastava, N Elmsherghi
Immunotherapy has revolutionized cancer care in the modern era of oncology. Research in immunotherapy has led to important advances in the treatment of melanoma, non-small cell lung cancer and other malignancies using checkpoint inhibition. Multiple systemic immunotherapies have been approved or are currently being investigated for the management of urothelial malignancies (1). Five antibodies targeting the programmed cell death protein 1--programmed cell death 1 ligand 1 (PD-1--PD-L1) pathway have been approved by the U...
December 2017: Drugs of Today
keyword
keyword
77517
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"